Funding

U.S. Government Considers Research Finance Rules

Published in TB and Outbreaks Week, August 29th, 2000

A new era of biotechnology economics that promises some scientists great wealth may cause conflicts of interest that affect patient safety and undermine medical research, experts say.

At a U.S. National Institutes of Health conference held August 15, 2000, speakers said that researchers who have a financial interest in drug companies may bias medical findings, put patients at risk, and erode public trust in the integrity of health science.

"If a crisis in confidence develops, if research subjects no longer feel safe, then medical research will grind to a halt," said Jane Henney, commissioner of the U.S. Food and Drug Administration.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2000-08-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry